Skip to Main Content

WASHINGTON — A new report on cannabidiol, or CBD, from the Food and Drug Administration, does little to clarify the agency’s rules for the hemp-derived product.

Companies hoping to put the marijuana-adjacent product in dietary supplements and cosmetic products have long complained that the FDA’s rules are not clear enough to justify their investment in the industry. The latest report, sent to Congress this week, does little to clear that up — it just says the agency is still “evaluating” its policies on the issue.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED